CIA
REGN icon

Capital Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439K Buy
569
+39
+7% +$29.9K 0.01% 516
2025
Q4 		$409K Buy
530
+53
+11% +$36K 0.01% 520
2025
Q3 		$268K Buy
477
+63
+15% +$35.6K ﹤0.01% 624
2025
Q2 		$217K Sell
414
-24
-5% -$13.4K ﹤0.01% 646
2025
Q1 		$278K Buy
438
+134
+44% +$92.2K 0.01% 568
2024
Q4 		$217K Sell
304
-11
-3% -$9.23K ﹤0.01% 597
2024
Q3 		$331K Buy
315
+20
+7% +$22.3K 0.01% 482
2024
Q2 		$310K Buy
295
+3
+1% +$2.91K 0.01% 483
2024
Q1 		$281K Sell
292
-3
-1% -$2.85K 0.01% 496
2023
Q4 		$259K Buy
295
+7
+2% +$5.76K 0.01% 504
2023
Q3 		$237K Sell
288
-18
-6% -$14.1K 0.01% 513
2023
Q2 		$220K Sell
306
-5
-2% -$3.85K 0.01% 492
2023
Q1 		$256K Buy
311
+24
+8% +$18.1K 0.01% 467
2022
Q4 		$207K Sell
287
-11
-4% -$8.12K 0.01% 526
2022
Q3 		$205K Buy
+298
New +$188K 0.01% 495
2022
Q2 		– Sell
-308
Closed -$215K – 590
2022
Q1 		$215K Buy
+308
New +$195K 0.01% 541
2016
Q1 		– Sell
-575
Closed -$312K – 441
2015
Q4 		$312K Buy
+575
New +$312K 0.03% 318

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital Investment Advisors's REGN Position: Q1 2026 in Review

Capital Investment Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 7.4% in Q1 2026, buying an estimated $29.9K and bringing the position to 569 shares worth $439K. The position accounts for 0.01% of the portfolio, ranked #516.

Capital Investment Advisors first reported a position in REGN in Q4 2015 and has held it in 17 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Capital Investment Advisors held 569 shares of Regeneron Pharmaceuticals worth $439K as of Q1 2026.
  • Capital Investment Advisors bought 39 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $29.9K.
  • Regeneron Pharmaceuticals made up 0.01% of Capital Investment Advisors's portfolio in Q1 2026, its #516 holding.
  • Capital Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 17 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.